甲磺酸伊马替尼

甲磺酸伊马替尼治疗3例Ph阳性慢性髓性白血病达细胞遗传学缓解后的疾病转化

Disease transformation in imatinib mesylate treated philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions

外科手术完整切除仍是GIST的首选治疗，甲磺酸伊马替尼是复发、转移性GIST的标准一线治疗药物。

Complete resection is still the first choice for GIST diseases . Imatinib mesylate is the first choice for relapsing and metastatic GIST .

甲磺酸伊马替尼在慢性髓样白血病患者中引起Sweet综合征1例

Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia

甲磺酸伊马替尼是一种蛋白质酪氨酸激酶抑制剂，用于治疗Ph染色体阳性慢性粒细胞白血病和恶性胃肠道间质肿瘤。

Imatinib mesilate is a protein-tyrosine kinase inhibitor approved for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and malignant gastrointestinal stromal tumors .

目的观察Ph阳性慢性髓性白血病（philadelphiachromosome-positivechronicmyelogenousleukemia，Ph+CML）患者在甲磺酸伊马替尼治疗达细胞遗传学缓解后的疾病进展。

Objective : To report disease transformation in 3 imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia ( Ph + CML ) patients who achieved cytogenetic response .

我们报道的该病例为淋巴细胞型HES，临床表现以皮肤受累为主，对糖皮质激素治疗反应较好，甲磺酸伊马替尼对该患者有一定疗效。

The case we report is lymphocytic HES , mainly skin involvement , better response to glucocorticoid treatment , efficacy of imatinib treatment .

目的评价甲磺酸伊马替尼治疗Ph阳性（Ph+）慢性粒细胞白血病（CML）慢性期的有效性与安全性。

Objective To evaluate the efficacy and safety of imatinib mesylate ( imatinib ) in patients with Philadelphia chromosome-positive ( Ph-positive ) chronic granulocytic leukemia ( CGL ) in chronic phase .

目的：探讨胃肠间质瘤（GIST）的CT表现及分子靶向药物甲磺酸伊马替尼（STI571）对胃肠间质瘤疗效的CT评价。

Objective : To explore CT in gastrointestinal stromal tumor ( GIST ) and evaluation the GIST treated with molecular targeted drug Imatinib mesylate ( STI 571 ) by CT .

术后患者均口服甲磺酸伊马替尼（IM）治疗，初始剂量均为400mg/d，服药时间1～24个月。

All patients are treated with imatinib mesylate after operations , the initial dose were 400mg / d , and taking time last from 1 to 24 months . Result : 1 .

诺华公司只是将其做成盐的形式甲磺酸伊马替尼（imatinibmesylate）以发挥药效：使人体吸收药物容易30%。

Only by making it in salt form , imatinib mesylate , did Novartis have a proper drug : the body absorbed the medicine 30 % more easily .

甲磺酸伊马替尼抑制博莱霉素诱导小鼠肺纤维化的作用机制

Imatinib mesylate inhibits bleomycin-induced pulmonary fibrosis in mice : the mechanism

目的研究和改进甲磺酸伊马替尼的合成工艺。

OBJECTIVE To study and improve the synthesis of imatinib mesylate .

甲磺酸伊马替尼治疗51例晚期胃肠道间质瘤患者的疗效分析

Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors

甲磺酸伊马替尼治疗国人胃肠间质瘤的临床研究

Clinical Study of Chinese Gastrointestinal Stromal Tumors Patients Treated with Imatinib Mesylate

甲磺酸伊马替尼治疗复发或转移性胃肠间质瘤

Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor

三氧化二砷逆转甲磺酸伊马替尼对K562/MDR1耐药的实验研究

The Experimental Investigation of Arsenic Trioxide Reverse Imatinib Mesylate Resistance in K562 / MDR1

甲磺酸伊马替尼治疗引发玫瑰糠疹样皮疹3例

Pityriasis rosea - like eruption during treatment with imatinib mesylate : Description of 3 cases

甲磺酸伊马替尼治疗慢性粒细胞白血病122例疗效评价

Efficacy and safety evaluation of imatinib in the treatment of 122 cases of chronic myeloid leukemia

高嗜酸性粒细胞综合征患者粒细胞JAK/STAT信号转导途径的激活及对甲磺酸伊马替尼的治疗反应

The activation of JAK / STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib

甲磺酸伊马替尼治疗对铂类和紫杉烷耐药的复发性卵巢上皮癌和原发性腹膜癌患者的Ⅱ期试验

Phase ⅱ trial of imatinib mesylate in patients with recurrent platinum-and taxane-resistant epithelial ovarian and primary peritoneal cancers

甲磺酸伊马替尼致三度房室传导阻滞盐酸左旋布比卡因复合枸橼酸舒芬太尼、咪唑安定用于剖宫产术后硬膜外自控镇痛的效果

Atrioventricular block ⅲ caused by imatinib mesylate Effect of Levobupivacaine Combined with Sufentanil and Midazolam in Patient-controlled Epidural Analgesia after Cesarean Section